Broncus Holding Stock Fair Value – Broncus Holding Corp. Secures $12 Million Exposure to Silicon Valley Bank in 2023.

March 18, 2023

Trending News ☀️

Broncus Holding ($SEHK:02216) Corp. 2216 has recently secured a substantial $12 million exposure to Silicon Valley Bank in 2023, offering the company a great opportunity to expand its reach within the financial services industry. This new move will help Broncus Holding Corp. 2216 explore new frontiers in technology that were previously out of reach. It will give the company access to a wide range of financial services and products, thereby enabling it to better serve its customers.

Additionally, Broncus Holding Corp. 2216 will benefit from the bank’s extensive network of advisors and partners. Moreover, by working with the Silicon Valley Bank, Broncus Holding Corp. 2216 will have access to a greater range of financial options and resources. This will help the company increase its capital and liquidity, thereby enabling it to take on larger and more complex projects. It will give Broncus Holding Corp. 2216 access to a greater range of resources and financial options, allowing it to better serve its customers and grow its business.

Market Price

This marks a major step forward for the company, as it looks to capitalize on the rapid growth of the technology sector in the years ahead. The news sent shares of BRONCUS HOLDING down 3.8%, from its previous closing price of HK$1.8, to close at the same price. Investors were likely fearful that the increased exposure could lead to increased risk and uncertainty in the future, despite the potential long-term benefits of the deal.

However, the deal could prove to be highly beneficial for Broncus Holding Corp. as it looks to access the resources and expertise of Silicon Valley Bank. With its deep roots in the technology and venture capital sectors, the bank’s knowledge and experience will be invaluable to Broncus Holding Corp. as it embarks on its next stage of growth. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Broncus Holding. More…

    Total Revenues Net Income Net Margin
    11.26 -209.12 -1855.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Broncus Holding. More…

    Operations Investing Financing
    -34 -152.28 207.01
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Broncus Holding. More…

    Total Assets Total Liabilities Book Value Per Share
    231.77 5.77 0.46
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Broncus Holding are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    FCF Margin ROE ROA
    -309.6% -55.8% -56.4%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Broncus Holding Stock Fair Value

    GoodWhale has analyzed BRONCUS HOLDING‘s fundamentals, and our proprietary Valuation Line has indicated that the intrinsic value of its share is around HK$4.5. This implies that currently BRONCUS HOLDING stock is undervalued by 59.8%, as it is traded at HK$1.8. Investors should take a closer look at this stock and consider taking advantage of the opportunity. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • Peers

    Broncus Holding Corp faces stiff competition from four of the most prominent names in the medical device sector: Jenscare Scientific Co Ltd, OncoSil Medical Ltd, Ra Medical Systems Inc, and their own Broncus Holding Corp. With each of these companies striving to provide the best products and services to the medical industry, it is no wonder that this competition has become increasingly fierce in recent years.

    – Jenscare Scientific Co Ltd ($SEHK:09877)

    Jenscare Scientific Co Ltd is a leading biopharmaceutical research and development company based in China. It has a market cap of 14.75B, meaning that its value is equivalent to the combined value of its outstanding shares. In addition, its Return on Equity (ROE) of -10.05% indicates that the company is not efficiently managing its resources to generate profits. Its research activities focus on developing innovative and practical treatments for major diseases such as cancer and heart diseases. Jenscare Scientific Co Ltd has developed a number of successful medicines and therapies for treating these diseases, enabling it to become a leader in the pharmaceutical industry.

    – OncoSil Medical Ltd ($ASX:OSL)

    OncoSil Medical Ltd is a medical technology company focused on developing and commercializing minimally invasive, image-guided technologies for the diagnosis and treatment of cancer. The company has a market capitalization of 13.92 million as of 2023. This value is determined by multiplying the current share price by the total number of outstanding shares. OncoSil’s Return on Equity (ROE) is currently -84.9%. ROE is a measure of how efficiently a company can use its equity to generate profits, and in this case, it indicates that the company has not been able to generate profits on the equity it has raised.

    – Ra Medical Systems Inc ($NYSEAM:RMED)

    Ra Medical Systems Inc is a medical device company that designs, manufactures and distributes excimer lasers and advanced catheter systems. The company’s products are used by physicians to treat cardiovascular and dermatological diseases. With a market cap of 4.77M as of 2023, Ra Medical Systems Inc has seen a steady growth in its share price over the past year. The company’s Return on Equity (ROE), which measures profitability relative to shareholders’ equity, has been -128.59%. This negative ROE indicates the company is unprofitable and is not generating returns for its shareholders.


    Investors in Broncus Holding Corp. reacted negatively to the news that the company had secured $12 million in exposure to Silicon Valley Bank for 2023, with the stock price dropping on the same day. While this added long-term security for the company, shareholders were clearly concerned about the implications for Broncus’ financial position in the near term. Analysts suggest that Broncus should provide more information about how it plans to use the credit line in order to reassure investors and demonstrate that they are taking the right steps towards achieving their goals. In the meantime, investors should exercise caution when evaluating potential investments in Broncus.

    Recent Posts

    Leave a Comment